Sep 28, 2022 | 2022, Investors, Press Releases
More detailsSep 28, 2022 | 2022, Past Events
Philogen held a virtual briefing on 29 September 2022 at 10:00 ET / 15:00 BST / 16:00 CEST following the Board of Directors’ approval of the Half-Yearly Financial Report as of 30 June 2022. Prof. Dr. Dario Neri, Chief Executive Officer, Dr. Laura Baldi, Chief...Sep 26, 2022 | 2022, Investors, Press Releases
More detailsSep 19, 2022 | 2022, Investors, Press Releases
More detailsSep 15, 2022 | 2022, Press Releases, Scientific
The study shows selective tumor uptake of IL12-7NP2 and potent antitumor activity as single agent and in combination with immune checkpoint inhibitors. The product is well tolerated when administered to non-human primates. More detailsSep 12, 2022 | 2022, Investors, Press Releases
More details
Recent Comments